FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.
What happened
FDA reviewed the company’s website in December 2025 and found it offered compounded (custom-mixed) semaglutide and tirzepatide drug products. FDA said labels pictured on the site named Deluxe IV and Aesthetics as the compounder even though it is not, and that website claims comparing the products to Ozempic, Mounjaro, Wegovy, Rybelsus, and Zepbound were false or misleading, including by implying FDA approval.
What FDA found
The website’s pictured labels named Deluxe IV and Aesthetics as the compounder of the semaglutide and tirzepatide products, but the letter says it is not the compounder.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 CFR § 201.1(h)(2)The website claims that the compounded products contain the same active ingredient as Ozempic and Mounjaro, which FDA says falsely implies FDA approval or evaluation.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website says semaglutide is the active ingredient in Ozempic, Rybelsus, and Wegovy, and tirzepatide is the active ingredient in Mounjaro and Zepbound.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says the misbranded products were introduced or delivered into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]FDA also notes that receiving misbranded drugs or delivering them is prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA asks the company to take immediate action and, within 15 working days of receipt, send a written response to the Office of Compounding Quality and Compliance describing corrective steps, identifying the entities that produce the products, providing sample labeling, and addressing or modifying the website claims.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- med spas and aesthetic clinics advertising compounded drugs
- compounders whose products are resold or advertised by others
This is a summary. Read the original letter on fda.gov.